Tumour lysis syndrome: new therapeutic strategies and classification - PubMed (original) (raw)
Review
Tumour lysis syndrome: new therapeutic strategies and classification
Mitchell S Cairo et al. Br J Haematol. 2004 Oct.
Free article
Abstract
Tumour lysis syndrome (TLS) describes the metabolic derangements that occur with tumour breakdown following the initiation of cytotoxic therapy. TLS results from the rapid destruction of malignant cells and the abrupt release of intracellular ions, nucleic acids, proteins and their metabolites into the extracellular space. These metabolites can overwhelm the body's normal homeostatic mechanisms and cause hyperuricaemia, hyperkalaemia, hyperphosphaetemia, hypocalcaemia and uraemia. TLS can lead to acute renal failure and can be life-threatening. Early recognition of patients at risk and initiation of therapy for TLS is essential. There is a high incidence of TLS in tumours with high proliferative rates and tumour burden such as acute lymphoblastic leukaemia and Burkitt's lymphoma. The mainstays of TLS prophylaxis and treatment include aggressive hydration and diuresis, control of hyperuricaemia with allopurinol prophylaxis and rasburicase treatment, and vigilant monitoring of electrolyte abnormalities. Urine alkalinization remains controversial. Unfortunately, there have been few comprehensive reviews on this important subject. In this review, we describe the incidence, pathophysiological mechanisms of TLS and risk factors for its development. We summarise recent advances in the management of TLS and provide a new classification system and recommendations for prophylaxis and/or treatment based on this classification scheme.
Copyright 2004 Blackwell Publishing Ltd
Similar articles
- An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
Mughal TI, Ejaz AA, Foringer JR, Coiffier B. Mughal TI, et al. Cancer Treat Rev. 2010 Apr;36(2):164-76. doi: 10.1016/j.ctrv.2009.11.001. Epub 2009 Dec 23. Cancer Treat Rev. 2010. PMID: 20031331 Review. - Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Cairo MS, et al. Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16. Br J Haematol. 2010. PMID: 20331465 Review. - Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Coiffier B, et al. J Clin Oncol. 2008 Jun 1;26(16):2767-78. doi: 10.1200/JCO.2007.15.0177. J Clin Oncol. 2008. PMID: 18509186 Review. - Tumor lysis syndrome in elderly.
Pumo V, Sciacca D, Malaguarnera M. Pumo V, et al. Crit Rev Oncol Hematol. 2007 Oct;64(1):31-42. doi: 10.1016/j.critrevonc.2007.05.003. Epub 2007 Jul 19. Crit Rev Oncol Hematol. 2007. PMID: 17658268 Review. - [Tumor lysis syndrome].
Jeddi R, Ben Abdennebi Y, Allani B, Belakhal R, Aissaoui L, Ben Abid H, Ali ZB, Meddeb B. Jeddi R, et al. Tunis Med. 2007 Feb;85(2):174-6. Tunis Med. 2007. PMID: 17665670 Review. French.
Cited by
- Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practice.
Mohamad J, Bouroumeau A, McKee TA, Mach N, Samii K, Chamuleau M, Stenner F, Tamburini J, Lang N. Mohamad J, et al. Cancer Rep (Hoboken). 2024 Oct;7(10):e1983. doi: 10.1002/cnr2.1983. Cancer Rep (Hoboken). 2024. PMID: 39410860 Free PMC article. - Effectiveness of a Single Fixed Dose of 3 mg Rasburicase for the Prevention and Management of Hyperuricemia in Tumor Lysis Syndrome in Adults With Cancer.
Bakhsh S, Khan MA, Alshamrani M, Mufti R, Naeem A, AlMansour M, Alsaeed A, Alahmari M, Aseeri M. Bakhsh S, et al. Cureus. 2024 Sep 4;16(9):e68664. doi: 10.7759/cureus.68664. eCollection 2024 Sep. Cureus. 2024. PMID: 39376806 Free PMC article. - Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Li D, Qin C, Wang H, Du D, Wang Y, Du Q, Liu S. Li D, et al. Ther Adv Drug Saf. 2024 Sep 6;15:20420986241274909. doi: 10.1177/20420986241274909. eCollection 2024. Ther Adv Drug Saf. 2024. PMID: 39247253 Free PMC article. - Unexpected Rasburicase-Induced Hemolysis in a Patient With Normal Glucose-6-Phosphate Dehydrogenase Activity.
Musleh Ud Din S, Shan K, Rehman TU, Ivanov S, Vargas-Madueno FM. Musleh Ud Din S, et al. J Med Cases. 2024 Sep;15(9):231-236. doi: 10.14740/jmc4277. Epub 2024 Aug 22. J Med Cases. 2024. PMID: 39205694 Free PMC article. - Tumour lysis syndrome.
Howard SC, Avagyan A, Workeneh B, Pui CH. Howard SC, et al. Nat Rev Dis Primers. 2024 Aug 22;10(1):58. doi: 10.1038/s41572-024-00542-w. Nat Rev Dis Primers. 2024. PMID: 39174582 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources